Cannon v. Blue Cross and Blue Shield of Massachusetts, Inc.

132 F.4th 86
CourtCourt of Appeals for the First Circuit
DecidedMarch 19, 2025
Docket24-1862
StatusPublished
Cited by1 cases

This text of 132 F.4th 86 (Cannon v. Blue Cross and Blue Shield of Massachusetts, Inc.) is published on Counsel Stack Legal Research, covering Court of Appeals for the First Circuit primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Cannon v. Blue Cross and Blue Shield of Massachusetts, Inc., 132 F.4th 86 (1st Cir. 2025).

Opinion

United States Court of Appeals For the First Circuit

No. 24-1862

SCOTT CANNON, individually and as the Personal Representative of the Estate of Blaise Cannon,

Plaintiff, Appellant,

v.

BLUE CROSS AND BLUE SHIELD OF MASSACHUSETTS, INC.,

Defendant, Appellee.

APPEAL FROM THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF MASSACHUSETTS

[Hon. Denise J. Casper, U.S. District Judge]

Before

Aframe, Lynch, and Howard, Circuit Judges.

Louis C. Schneider, with whom Thomas Law Offices, PLLC, Heather M. Bonnet-Hébert and Feingold Bonnet-Hébert were on brief, for appellant. Brooks R. Magratten, with whom Stanley F. Pupecki and Pierce Atwood LLP were on brief, for appellees.

March 19, 2025 LYNCH, Circuit Judge. Scott Cannon, individually and as

the personal representative of the estate of Blaise Cannon, appeals

from the grant of summary judgment on ERISA preemption grounds to

defendant Blue Cross and Blue Shield of Massachusetts ("BCBS") on

his state law wrongful death/punitive damages claim. See Mass.

Gen. Laws ch. 229 § 2. His assertion is that BCBS's denial of

insurance coverage for a particular inhaler for Blaise Cannon

("Blaise") prematurely caused Blaise's later death from

asthma-related complications. The parties agree that Blaise was

a beneficiary of his partner's BCBS health insurance policy through

the partner's employer, and that policy was covered by the Employee

Retirement Income Security Act of 1974 ("ERISA"), 29 U.S.C. §§ 1001

et seq. Cannon's primary contention is that Rutledge v. Pharm.

Care Mgmt. Ass'n, 592 U.S. 80 (2020), overrules prior law and

requires reinstatement of the wrongful death/punitive damages suit

(the "claim"). We affirm the district court's holding that as a

matter of law ERISA preempts his claim.

Two provisions of ERISA are relevant to Cannon's appeal,

each of which provides a basis for preemption. ERISA expressly

preempts "any and all State laws insofar as they may now or

hereafter relate to any employee benefit plan." 29 U.S.C.

§ 1144(a). This is often called statutory preemption. See Metro.

Life Ins. Co. v. Mass., 471 U.S. 724, 747 (1985). "The term 'State

law' includes all laws, decisions, rules, regulations, or other

- 2 - State action having the effect of law, of any State." Id.

§ 1144(c)(1). A state cause of action may also be preempted if it

conflicts with the remedial scheme established by 29 U.S.C.

§ 1132(a), which provides that a "civil action may be brought[] by

a participant or beneficiary . . . to recover benefits due to him

under the terms of his plan, to enforce his rights under the terms

of the plan, or to clarify his rights to future benefits under the

terms of the plan."

I.

The facts are drawn from the record and discovery as to

Blaise's health insurance policy.

Blaise was insured as a covered dependent of his domestic

partner's BCBS group health insurance policy. On March 18, 2020,

Blaise, through his doctor, sought coverage for a Wixela Inhub

inhaler to treat his asthma. On March 25, 2020, BCBS denied

coverage, explaining:

Our Pharmacy Operations Unit considered the material your doctor provided. Coverage of Wixela Inhub was requested for the treatment of asthma (breathing disorder). We could not approve coverage of this medication because there was no documentation of trying one prescription inhaled steroid, inhaled beta-agonist, inhaled mast cell stabilizer, oral albuterol, or theophylline product within the previous 130 days and there was no documentation of trying two of the following: Dulera (Prior Authorization required) and/or Symbicort (Prior Authorization required) and/or fluticasone/salmeterol (generic for

- 3 - Airduo -- Prior Authorization required) by the patient.

Blaise did not take any appeal from this denial of benefits.

Following Blaise's death, Cannon brought six state law

claims against BCBS: declaratory judgment, breach of contract, bad

faith, wrongful death, punitive damages, and loss of consortium.

BCBS removed the case to federal court and moved to dismiss the

action on the basis of ERISA preemption, and the district court

allowed Cannon a brief period of limited discovery. On November

7, 2023, the court denied the motion to dismiss "without prejudice

to BCBS raising the issue of ERISA preemption in a motion for

summary judgment." Cannon v. Blue Cross and Blue Shield of Mass.,

Inc., No. 23-cv-10950, 2024 WL 3902835, at *1 (D. Mass. Aug. 22,

2024). After Cannon conducted a Rule 30(b)(6) deposition of BCBS,

on February 28, 2024, BCBS moved for summary judgment. Conceding

ERISA preempted most of his claims, Cannon argued that his wrongful

death claim and corresponding punitive damages claim were not

preempted and survived.

On August 22, 2024, the district court held that ERISA

statutorily preempted the wrongful death claim because "the cause

of action 'relate[d] to' th[e] employee benefit plan" covered by

ERISA. Id. at *2 (quoting Hampers v. W.R. Grace & Co., Inc., 202

F.3d 44, 49 (1st Cir. 2000)). The claim "related" to Blaise's

health insurance policy because the district court "would be

- 4 - required to consult the Policy to resolve [it] and because [it]

arose from the alleged improper denial of benefits." Id. Further,

the court held that the claim "is an action for damages related to

a breach of plan and is therefore precisely the type of alternative

enforcement mechanism disallowed under ERISA [29 U.S.C.

§ 1132(a)]." Id. at *3.

II.

We review a grant of a motion for summary judgment de

novo, construing the evidence "in the light most congenial to the

nonmovant" and affirming the grant if the record "presents no

genuine issue as to any material fact and reflects the movant's

entitlement to judgment as a matter of law." Mullane v. U.S. Dep't

of Just., 113 F.4th 123, 130 (1st Cir. 2024) (quoting McKenney v.

Mangino, 873 F.3d 75, 80 (1st Cir. 2017)). Cannon did not respond

to BCBS's statement of material facts, so those facts are deemed

undisputed. See D. Mass. L.R. 56.1.

Cannon's claim is statutorily preempted under ERISA, 29

U.S.C. § 1144(a). "A law 'relates to' an employee benefit plan,

in the normal sense of the phrase, if it has a connection with or

reference to such a plan." Shaw v. Delta Air Lines, Inc., 463

U.S. 85, 96-97 (1983). The Supreme Court recently reaffirmed this

test in Rutledge, saying that "a state law relates to an ERISA

plan," and is preempted, "if it has a connection with or reference

to such a plan." 592 U.S. at 86 (quoting Egelhoff v. Egelhoff,

- 5 - 532 U.S. 141, 147 (2001)); see also Guerra-Delago v. Popular, Inc.,

774 F.3d 776, 781 (1st Cir. 2014) ("A law is preempted 'even if

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Orabona v. Santander Bank, N.A.
141 F.4th 1 (First Circuit, 2025)

Cite This Page — Counsel Stack

Bluebook (online)
132 F.4th 86, Counsel Stack Legal Research, https://law.counselstack.com/opinion/cannon-v-blue-cross-and-blue-shield-of-massachusetts-inc-ca1-2025.